IGC Pharma (IGC) received a Notice of Allowance from the United States Patent and Trademark Office for its patent application US 17/613,909. The patent application, IGC510, is for a proprietary method for treating individuals suffering from stammering, stuttering, or Tourette’s syndrome with THC and/or CBD.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IGC:
- IGC Pharma expands CALMA Phase 2 trial with Lynn Health Science Institute site
- IGC Pharma reports Q1 EPS (2c) vs. (3c) last year
- Igc Pharma’s Risky Venture: Navigating Financial Instability Amid Bitcoin Investment Plans
- IGC Pharma highlights preclinical data on IGC-M3
- Trump Trade: Nvidia, AMD said to pay U.S. cut from China chip sales